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Abstract 
Background: Milbemycins, produced from Streptomyces hygroscopicus subsp. aureolacrimosus and Streptomyces 
bingchenggensis, are 16‑membered macrolides that share structural similarity with avermectin produced from Strepto-
myces avermitilis. Milbemycins possess strong acaricidal, insecticidal, and anthelmintic activities but low toxicity. Due 
to the high commercial value of the milbemycins and increasing resistance to the avermectins and their derivatives, 
it is imperative to develop an efficient combinatorial biosynthesis system exploiting an overproduction host strain to 
produce the milbemycins and novel analogs in large quantities.
Results: The respective replacement of AveA1 and AveA3 (or module 7 in AveA3) of the avermectin polyketide syn‑
thase (PKS) in the avermectin high‑producing strain S. avermitilis SA‑01 with MilA1 and MilA3 (or module 7 in MilA3) 
of the milbemycin PKS resulted in the production of milbemycins A3, A4, and D in small amounts and their respective 
C5‑O‑methylated congener milbemycins B2, B3, and G as major products with total titers of approximately 292 mg/l. 
Subsequent inactivation of the C5‑O‑methyltransferase AveD led to a production of milbemycins A3/A4 (the main 
components of the commercial product milbemectin) in approximately 225 and 377 mg/l in the flask and 5 l fer‑
menter culture, respectively, along with trace amounts of milbemycin D.
Conclusions: We demonstrated that milbemycin biosynthesis can be engineered in the avermectin‑producing S. 
avermitilis by combinatorial biosynthesis with only a slight decrease in its production level. Application of a similar 
strategy utilizing higher producing industrial strains will provide a more efficient combinatorial biosynthesis system 
based on S. avermitilis for further enhanced production of the milbemycins and their novel analogs with improved 
insecticidal potential.
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Background
The milbemycins and avermectins are structurally related 
16-membered macrolides with excellent anthelmintic 
and insecticidal activities (Fig.  1). Avermectins, pro-
duced by Streptomyces avermitilis, are composed of a 
pentacyclic macrolactone and a disaccharide of methyl-
ated l-oleandrose [1, 2]. Avermectin B1 homologs which 
possess a C5-hydroxy group and a double bond between 
C22–C23 are the most potent congeners among the eight 
structurally related avermectin compounds [3]. Conse-
quently, the semisynthetic 22,23-dihydroavermectin B1 
(ivermectin) (Fig. 1) was developed and introduced to the 
market for use as an antiparasitic agent [4]. Furthermore, 
the increase of avermectin and ivermectin-resistant 
insects has led to the development of a series of avermec-
tin analogs including selamectin, abamectin, emamectin, 
and doramectin [5]. The milbemycins were originally 
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isolated from Streptomyces hygroscopicus subsp. aureol-
acrimosus [6] and recently from Streptomyces bingcheng-
gensis [7, 8]. While the structures of milbemycins are 
similar to those of the avermectins, a bisoleandrosyl sub-
stituent appended to the C13 position of the avermectins’ 
macrolide ring does not exist in milbemycins. Only a 
single bond at the C22–C23 position is found in milbe-
mycins, whereas the avermectins can possess a single or 
double bond at the same position. In addition, several 
different alkyl chains are attached at the C25 position of 
these compounds (Fig. 1). They possess broad acaricidal 
and insecticidal activities with relatively lower toxicity 
to non-target organisms [9, 10]. Milbemectin (a mixture 
of milbemycins A3 and A4) was first commercialized 
as an acaricide [11]. Subsequently, a series of milbemy-
cins analogs, such as lepimectin (13-(α-methoxyimino
phenylacetoxy)milbemycin) [12] and milbemycin oxime 
(5-oxime derivate of milbemycins A3/A4) [13], have been 
developed.
The biosynthetic gene clusters of the milbemycins in 
Streptomyces nanchangensis NS3226 (milbemycins α11, 
α13, α14, β1, and β9 are identical to meilingmycins A to 
E, respectively, produced by S. nanchangensis) [14] and S. 
bingchenggensis [15] (Fig. 2a) as well as the avermectins in 
S. avermitilis [16] (Fig. 2b) were characterized. The milbe-
mycin polyketide synthase (PKS) consists of four giant 
multifunctional polypeptides (MilA1, MilA2, MilA3, and 
MilA4). Its modular composition and gene organization 
are similar to those of avermectin PKS which possesses 
one loading module and twelve extension modules. The 
difference lies in the fact that the milA1 gene encoding 
the loading module and two extension modules is located 
55- and 62-kb apart from the other three PKS genes in 
the milbemycin gene cluster of S. nanchangensis and S. 
bingchenggensis, respectively, and there are several sig-
nificant differences between the two biosynthetic genes 
at the domain level which directs the structural diver-
sity of these molecules (Fig.  2). Specifically, the starting 
unit preference of the acyltransferase (AT) domain of the 
loading module, which determines the C25 substituents 
of the compounds, is different. Incorporation of 2-meth-
ylbutyryl-CoA or isobutyryl-CoA as a starter unit results 
Fig. 1 The structures of a Avermectins and ivermectins, b Milbemycins
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in an isobutyl or isopropyl side chain in avermectin “a” 
and “b” components, respectively. In contrast, a methyl, 
ethyl, or isopropyl side chain at the C25 position of 
milbemycin results from the incorporation of an acetyl-
CoA, propionyl-CoA, or isobutyryl-CoA, respectively. 
In addition, the unsaturated bond at the C22–C23 posi-
tion in avermectin “1” components or the C23-hydroxy 
group in avermectin “2” components results from a com-
pletely inactive dehydratase (DH) domain in module 2 
of the avermectin PKS and the unique activity of AveC 
catalyzing the dehydration-coupled spirocyclization 
[17]. On the other hand, the C22–C23 saturated bond of 
milbemycin is formed by the action of a fully active DH 
domain and enoylreductase (ER) domain in module 2 
of milbemycin PKS. Additionally, the AveC counterpart 
MeiC in the meilingmycin biosynthetic gene cluster has 
spirocyclase activity but lacks the optional dehydratase 
activity [17]. Moreover, the DH domain of module 7 in 
avermectin PKS is presumed to be nonfunctional and is 
responsible for C13-hydroxy group formation through 
which a bisoleandrosyl substituent is connected, but the 
active DH and ER domains of milbemycin PKS generate a 
fully saturated structure at the corresponding position of 
milbemycin (Fig. 2).
There has been great interest in improving the yield 
of milbemycins A3 and A4 due to their prominent 
activity and commercial value. A combined approach 
of classical mutagenesis by ultraviolet irradiation or 
Fig. 2 Gene and module organizations of avermectin and milbemycin biosynthetic gene clusters. a Milbemycin PKS in S. bingchenggensis BCW‑1. 
The PKS genes (milA1, milA2, milA3, and milA4) for milbemycin biosynthesis were indicated with yellow. b Avermectin PKS in S. avermitilis SA‑01. The 
PKS genes (aveA1, aveA2, aveA3, and aveA4) for the biosynthesis of the avermectin core skeleton were shown with green. The aveD gene that was 
engineered in this study was shown with red. Empty circles indicate nonfunctional domains
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N-methyl-N′-nitroso-N-nitrosoguanidine and rational 
screening led to the mutant strain S. bingchenggensis 
with 80% enhanced production of milbemycins A3 and 
A4 compared to the parent strain [18]. However, this 
traditional method required time-consuming and labori-
ous work. A simple metabolic engineering strategy also 
increased milbemycin A3/A4 titers in S. bingchenggensis. 
Deletion of the milD gene encoding a C5-O-methyltrans-
ferase and the nanLD gene encoding the loading module 
of the PKS for nanchangmycin (another major polyketide 
co-produced by S. bingchenggensis) constructed a mutant 
strain that produces approximately 74% more milbemy-
cins A3/A4 than the initial S. bingchenggensis strain [19]. 
Although the genome of S. bingchenggensis was reported 
[15], a limited understanding of this milbemycin-produc-
ing strain may delay further improvement of milbemycin 
A3/A4 titers by conventional metabolic engineering.
The use of previously optimized and well-characterized 
industrial overproduction strains as a heterologous host 
could be an efficient alternative for the enhanced production 
of natural products [20, 21]. Recently, replacement of aveA1 
encoding the loading module and first two extension mod-
ules with milA1 from the S. hygroscopicus HS023 industrial 
strain in a S. avermitilis G8-17 industrial strain produced 
3.4 g/l of 25-methyl-22,23-dihydroavermectin and 25-ethyl-
22,23-dihydroavermectin which displayed enhanced aca-
ricidal and nematicidal activities [22]. Similarly, the same 
avermectin analogs were obtained by replacement of the 
loading module and DH-KR (ketoreductase) domains of 
module 2 in AveA1 with the loading module and DH-ER-
KR domains of module 2 in MilA1 from S. bingchenggensis 
in another industrial avermectin-producing strain S. aver-
mitilis NA-108 with similar yields [23].
The structural similarity of avermectin and milbemycin 
motivated us to produce milbemycins through engineer-
ing of the avermectin biosynthetic pathway in an S. aver-
mitilis strain producing high levels of avermectins. In this 
report, we show that the S. avermitilis possessing previ-
ously enhanced avermectin production ability could be 
exploited for the production of milbemycins by replace-
ment of the avermectin AveA1 and AveA3 (or module 7) 
PKS with milbemycin MilA1 and MilA3 (or module 7) 
PKS, respectively. The subsequent inactivation of AveD, 
which is responsible for the post-PKS methylation of the 
C5-hydroxy group [24], led to the production of milbe-
mycins A3/A4 in great quantities in the engineered S. 
avermitilis strain.
Results
Design strategy for the engineered biosynthesis 
of milbemycins in S. avermitilis
To enable the biosynthesis of milbemycins in S. avermiti-
lis, the avermectin PKS should be engineered as follows: 
(1) the substrate specificity of the AT domain of the load-
ing module in AveA1 PKS should be altered to change 
the C25 side chains of avermectin to those present in 
the milbemycins, (2) the inactive DH domain of mod-
ule 2 in AveA1 should be engineered to be fully active 
DH-ER domains in order to introduce a single bond at 
the C22–C23 position, and (3) the nonfunctional DH 
domain of module 7 in AveA3 should be engineered to 
be completely functional DH-ER domains to change the 
C13-hydroxy group of avermectin to the saturated meth-
ylene of milbemycin, which also prevents the attachment 
of the bisoleandrosyl moiety to the C13-hydroxy group. 
In order to engineer the AT domain of the loading mod-
ule and the reductive domains of module 2, both domain/
module swapping and the replacement of the entire PKS 
subunit are possible. Therefore, in order to reduce the 
number of time-consuming double crossover processes, 
we decided to replace the AveA1 PKS on the chromo-
some in S. avermitilis SA-01, the previously optimized 
avermectin high-producing mutant strain, with MilA1 
from S. hygroscopicus subsp. aureolacrimosus NRRL 
5739 rather than individually replace the correspond-
ing domain/modules for changing the structures at C25 
and C22–C23 of avermectins. To introduce the desired 
change at C13 and because domain organizations of 
AveA3 and MilA3 containing modules 7, 8, 9 are identi-
cal except for module 7, we attempted both the replace-
ment of the PKS subunit AveA3 and swapping module 7 
to investigate which strategy would be better to maintain 
the functional integrity of the hybrid PKS and maximize 
the production of the milbemycins.
The docking domains at the termini of the PKS subu-
nits are in part responsible for mediating the interac-
tion of the corresponding subunits [25, 26]. To maintain 
the interaction between the substituted MilA1 and the 
downstream AveA2, the C-terminal docking domain 
of AveA1 was retained in the replaced MilA1. Similarly, 
the N- and C-terminal docking domains of AveA3 were 
maintained in the substituted MilA3 to keep the inter-
actions of the replaced MilA3 with the upstream AveA2 
and the downstream AveA4 (Fig. 3a). In the case of mod-
ule 7 replacement, the N-terminal docking domain of 
AveA3 was also retained to maintain the subunit interac-
tions between AveA2 and the module 7-replaced hybrid 
AveA3 (Fig.  3b). The boundaries of docking domains 
and the intermodular linker were chosen from the end 
of the highly conserved amino acid sequence of ACP 
(acyl carrier protein) domain in the upstream mod-
ule to the start of the highly conserved sequence in the 
ketosynthase (KS) domain in the downstream module. 
The engineered restriction sites for modular fusion were 
designed not to change amino acid residues to minimize 
their adverse effects on the function of hybrid PKS and 
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Fig. 3 Engineered avermectin‑milbemycin hybrid PKSs and predicted milbemycin biosynthetic pathways. a Modular organization in AveA1 and 
AveA3 replacement strain S. avermitilis SAMA13. b Modular organization in AveA1 and AveA3‑module7 replacement strain S. avermitilis SAMA1M7. c 
Post‑PKS tailoring pathway of desired milbemycins. The sequential tailoring steps were shown as orange lines
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to keep its protein integrity (Additional file 1: Figure S1). 
The resulting S. avermitilis mutants in which AveA1 and 
AveA3 (or module 7 of AveA3) were replaced with MilA1 
and MilA3 (or module 7 of MilA3), respectively, were 
expected to produce milbemycins through the post-PKS 
modification of the engineered polyketide chain by AveC 
(spirocyclase with optional dehydratase activity), AveE 
(cytochrome P450 involved in furan ring closure at C6–
C8), AveF (dehydrogenase involved in C5-keto reduc-
tion), and AveD (C5-O-methyltransferase) of the host S. 
avermitilis strain (Fig. 3c).
Construction of aveA1 and aveA3 (module 7) replacement 
mutant strains
To begin, we constructed the mutant strain S. avermitilis 
SAMA1 by replacing aveA1 in S. avermitilis SA-01 with 
milA1 from S. hygroscopicus subsp. aureolacrimosus. 
The temperature-sensitive Escherichia coli-Streptomyces 
shuttle vector pKC1139 [27] containing an apramycin 
resistance marker was used for gene replacement. The 
aveA1 replacement plasmid pSAMA1 was constructed 
to express the loading module and modules 1 and 2 of 
MilA1 efficiently by maintaining the promoter region of 
the aveA1 gene (Additional file 1: Figure S1a) and to retain 
the C-terminal docking domain of AveA1 for the main-
tenance of its interaction with downstream PKS AveA2 
(Fig. 3a; Additional file 1: Figure S1a). Plasmid pSAMA1 
was transferred by conjugation from E. coli ET12567/
pUZ8002 [28] to S. avermitilis SA-01 and the double 
crossover mutant was selected by their apramycin-sensi-
tive phenotype which was verified by PCR analysis. The 
expected 1.6-kb DNA fragment covering the promoter 
of aveA1 and the AT domain of the loading module in 
MilA1 was obtained from the genomic DNA of S. aver-
mitilis SAMA1 with the primers A1seq-1F and A1seq-1R 
(Additional file  2: Table S1), while no PCR product was 
generated from the genomic DNA of S. avermitilis SA-01. 
Similarly, the 1.5-kb DNA fragment covering the ACP 
domain of module 2 in MilA1 and the C-terminal docking 
domain of AveA1 was detected from the genomic DNA 
of S. avermitilis SAMA1 using the primers A1seq-2F and 
A1seq-2R (Additional file  2: Table S1), whereas no PCR 
product was observed from the genomic DNA of S. aver-
mitilis SA-01. As a negative control, no PCR product cor-
responding to the internal region of AveA1 was amplified 
from the genomic DNA of S. avermitilis SAMA1 using 
the primers A1seq-ncF and A1seq-ncR (Additional file 2: 
Table S1), while a 2.8-kb DNA fragment containing the 
internal region of AveA1 was detected from the S. aver-
mitilis SA-01 genomic DNA (Fig.  4a, b). The sequenc-
ing of the PCR products further confirmed that aveA1 
was replaced with milA1 while the promoter and dock-
ing domain regions were maintained as designed. Next, 
using the replacement plasmid pSAMA13 and a similar 
DNA replacement approach, the AveA3 in the avermec-
tin PKS of S. avermitilis SAMA1 was substituted with 
MilA3 where the N- and C-terminal docking domains 
of AveA3 were retained, yielding a mutant strain S. aver-
mitilis SAMA13 (Fig.  3a; Additional file  1: Figure S1b). 
The genotype of the apramycin-sensitive double crossover 
mutant was confirmed by PCR analysis and sequencing 
of the PCR products. The predicted 1.4-kb DNA frag-
ment covering the C-terminal docking domain of AveA3 
as well as the ACP and part of the KR domains of mod-
ule 9 in MilA3, and a 4.9-kb DNA fragment covering 
the part of module 7 (KS, AT, DH, partial ER domains) 
in MilA3 and the N-terminal docking domain in AveA3 
were amplified from the genomic DNA of S. avermitilis 
SAMA13 with primers A3seq-1F/A3seq-1R and A3seq-
2F/A3seq-2R, respectively (Additional file  2: Table S1). 
However, no corresponding PCR products were detected 
from the genomic DNA of S. avermitilis SAMA1. Again, 
no PCR product containing the internal region of AveA3 
was detected from the genomic DNA of S. avermitilis 
SAMA13 using the primers A3seq-ncF and A3seq-ncR 
(Additional file 2: Table S1), while a 1.9-kb DNA fragment 
covering the internal region of AveA3 was amplified from 
the S. avermitilis SAMA1 genomic DNA (Fig. 4c, d). The 
organic extracts obtained from the 14-day-old culture 
of S. avermitilis SAMA13 strain were analyzed by ultra-
performance liquid chromatography (UPLC) combined 
with quadrupole-time of flight high resolution mass spec-
trometry (qTOF-HR-MS) under negative electrospray 
ionization (ESI) mode. Peaks corresponding to milbe-
mycins A3 (selected for m/z  =  527.3014), A4 (selected 
for m/z  =  541.3171), B2 (selected for m/z  =  541.3171), 
D (selected for m/z  =  555.3327), B3 (selected for 
m/z  =  555.3327), and G (selected for m/z  =  569.3484) 
were observed at retention times of 7.5, 8.9, 11.2, 12.8, 
13.1, and 14.6  min, respectively (Fig.  5a). The respec-
tive retention times and MS/MS fragmentation patterns 
of milbemycins A3, A4, and D produced by the mutant 
strain S. avermitilis SAMA13 were identical to those of 
standard milbemycins A3, A4, and D. The identities of 
other milbemycin congeners obtained were confirmed by 
their molecular weights and MS/MS fragmentation pat-
terns (see below). The titers of total milbemycins were 
291.5  mg/l and the major products were C5-O-methyl-
ated milbemycins B2, B3, and G (Table  1; Fig.  5a). Only 
trace amounts of oligomycin A, which is co-produced 
in S. avermitilis, was detected by UPLC-qTOF-HR-MS 
(Fig. 5a) and also high-performance liquid chromatogra-
phy (HPLC) analysis (Additional file 3: Figure S2a) under 
the culture conditions used in this study. The retention 
time and MS/MS fragmentation pattern of oligomycin 
A produced by the mutant strain S. avermitilis SAMA13 
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were identical to those of authentic oligomycin A (Addi-
tional file 4: Figure S3).
We also wished to investigate the effect of replac-
ing module 7 in Ave3 with the corresponding mod-
ule from MilA3 on the production of the milbemycins. 
The mutant strain S. avermitilis SAMA1M7, in which 
module 7 of Ave3 was replaced with that of MilA3 while 
the N-terminal docking domain of Ave3 was retained, 
was constructed using the plasmid pSAMA1M7 (Fig. 3b; 
Additional file 1: Figure S1c). The genotype of the S. aver-
mitilis SAMA1M7 strain was verified by PCR analysis 
and sequencing of the PCR products. The 1.6-kb DNA 
Fig. 5 UPLC‑qTOF‑HR‑MS/MS analysis of the extracts obtained from the mutant strains. a UPLC‑qTOF‑MS/MS chromatogram selected for 
m/z = 527.3014 corresponding to milbemycin A3 (A3), m/z = 541.3171 corresponding to milbemycin A4 (A4) and milbemycin B2 (B2), 
m/z = 555.3327 corresponding to milbemycin D (D) and milbemycin B3 (B3), m/z = 569.3484 corresponding to milbemycin G (G), and 
m/z = 789.5158 corresponding to oligomycin A (O), respectively, of culture extracts from the S. avermitilis SAMA13 and SAMA1M7 strains. b UPLC‑
qTOF‑MS/MS chromatogram selected for m/z = 527.3014, 541.3171, 555.3327, and 789.5158 corresponding to milbemycin A3 (A3), milbemycin A4 
(A4), milbemycin D (D), and oligomycin A (O), respectively, of culture extracts from the S. avermitilis SAMA1M7ΔD strain
Table 1 Production of milbemycins
ND Not detected
Strain Milbemycins (mg/l)
A3 A4 D B2 B3 G Total
SAMA13 7.3 ± 5.5 1.4 ± 1.1 1.3 ± 0.9 183.7 ± 3.0 76.0 ± 8.9 21.8 ± 5.1 291.5 ± 12.7
SAMA1M7 8.0 ± 0.6 1.4 ± 0.2 1.0 ± 0.1 193.1 ± 43.1 70.5 ± 7.2 17.7 ± 10.1 291.7 ± 58.0
SAMA1M7ΔD (flask) 156.6 ± 15.8 68.0 ± 1.9 22.5 ± 0.4 ND ND ND 247.1 ± 14.0
SAMA1M7ΔD (fermenter) 278.9 ± 10.0 98.4 ± 5.9 22.4 ± 9.5 ND ND ND 399.7 ± 20.0
(See figure on previous page.) 
Fig. 4 Construction of S. avermitilis mutant strains. a Schematic diagram of aveA1 replacement using pSAMA1, and b PCR analysis for the confirma‑
tion of S. avermitilis SAMA1. c Schematic diagram of aveA3 replacement using pSAMA13, and d PCR analysis for the confirmation of S. avermitilis 
SAMA13. e Schematic diagram of aveA3‑module7 replacement using pSAMA1M7, and f PCR analysis for the confirmation of S. avermitilis SAMA1M7
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fragment (covering the part of KS domain of module 
8 in AveA3 and the part of ACP domain of module 7 in 
MilA3) and the 2.1-kb DNA fragment (covering the KS 
domain of module 7 in MilA3 and N-terminal docking 
domain in AveA3) were detected from the genomic DNA 
of S. avermitilis SAMA1M7 with primers M7seq-1F/
M7seq-1R and M7seq-2F/M7seq-2R, respectively (Addi-
tional file  2: Table S1). However, no such PCR product 
was amplified from the genomic DNA of S. avermitilis 
SAMA1. The 0.6-kb DNA fragment corresponding to 
the part of module 7 in AveA3 was amplified from the 
genomic DNA of S. avermitilis SAMA1 using the prim-
ers M7seq-ncF and M7seq-ncR (Additional file  2: Table 
S1), while no such PCR product was detected from the 
S. avermitilis SAMA1M7 genomic DNA (Fig. 4e, f ). The 
component ratio and amounts of milbemycins produced 
from S. avermitilis SAMA1M7 were similar to those pro-
duced from S. avermitilis SAMA13 (Table 1).
Inactivation of aveD
In order to produce milbemycins A3 and A4, the pre-
dominant milbemectin components, as major products, 
the C5-O-methyltransferae AveD was inactivated in the 
S. avermitilis SAMA1M7 strain by inserting a stop codon 
140-bp downstream from the start codon of aveD using 
the plasmid pΔAveD (Additional file  5: Figure S4). The 
genotype of the resulting mutant strain S. avermitilis 
SAMA1M7ΔD was confirmed by sequencing the 1.1-kb 
PCR product covering the engineered stop codon with 
primers DDseq-F/DDseq-R (Fig.  6; Additional file  2: 
Table S1). The organic extracts obtained from the S. aver-
mitilis SAMA1M7ΔD strain were analyzed by UPLC-
qTOF-HR-MS, and peaks corresponding to milbemycins 
A3, A4, and D were observed (Fig.  5b). The titers of 
total milbemycins were approximately 247.1  mg/l and 
the major products were milbemycins A3 and A4 along 
with small amounts of milbemycin D. As expected, the 
production of C5-O-methylated milbemycins was com-
pletely abolished (Table  1; Fig.  5b). Again, only trace 
amounts of oligomycin A were observed by UPLC-
qTOF-HR-MS (Fig.  5b) and HPLC analysis (Additional 
file 3: Figure S2b).
The production of milbemycins from the S. avermiti-
lis SAMA1M7ΔD strain was monitored in the fermenter 
(5  l) throughout a 14-day incubation period (Fig.  7). 
The milbemycin production level of the S. avermitilis 
SAMA1M7ΔD strain showed a notable increase between 
2 and 10  days in the late exponential and stationary 
growth phase. It was observed that the carbon sources 
were continuously consumed during the stationary phase 
suggesting that carbon sources are required for the milbe-
mycin production and cell maintenance. The milbemy-
cin titers reached 399.7 mg/l after 12 days, which was an 
approximately 1.6-fold improvement compared to the 
flask culture. The ratio of milbemycins A3 and A4 was 
approximately 3:1 along with a small amount of milbemy-
cin D (Table 1).
Characterization of milbemycins by HR MS/MS analysis
Six milbemycin derivatives show relatively low affinities 
to protons during positive ESI mode. Although sodium 
adduct ions tend to be generated with the ion source 
under positive ESI mode, they were unacceptable for MS/
MS detection because of their unstable fragmentation 
patterns. Therefore, proton loss ions under the negative 
ESI mode were chosen as the parent ions for MS/MS.
The MS/MS spectra of milbemycins A3, A4, and D 
obtained from S. avermitilis SAMA13, SAMA1M7, 
and SAMA1M7ΔD were identical to those of authen-
tic milbemycins A3, A4, and D. The MS/MS spectra 
of milbemycins A3, A4, and D produced from S. aver-
mitilis SAMA1M7 and their fragmentation pathways 
are presented in Additional file 6: Figures S5a, S5b, and 
S5c, respectively. The molecular formula for milbemy-
cin A3 was confirmed to be C31H44O7 on the basis of 
the (−)-HRESIMS (high-resolution electrospray ioni-
zation mass spectrometry) peak at m/z  =  527.3034 
[M–H]− (calcd 527.3014 for C31H43O7−). Milbemycin 
A3 had its proton loss precursor peak at m/z = 527.3034, 
which was accompanied by several product ions (Addi-
tional file  6: Figures S5a). The molecular formula for 
milbemycin A4 was determined to be C32H46O7 on the 
basis of (−)-HRESIMS proton loss precursor peak at 
m/z = 541.3170 [M–H]− (calcd 541.3171 for C32H45O7−), 
which was fragmented into several product ions (Addi-
tional file 6: Figures S5b). The milbemycin D formula was 
determined to be C33H48O7 on the basis of (−)-HRESIMS 
peak at m/z  =  555.3311 [M–H]− (calcd 555.3327 for 
C33H47O7−), which also produced several product ions 
(Additional file  6: Figures S5c). There are fragment ions 
including m/z =  321.1860 and 109.0295 common to all 
three compounds, and the existence of characteristic 
fragmentation patterns of milbemycins A3, A4, and D 
(m/z  =  143.1078, 157.1234, and 171.1391, respectively) 
shows that the structural difference stems from the 
methyl, ethyl, and isopropyl moieties on C25. In addition, 
the corresponding fragment ions within the three milbe-
mycins A3, A4, and D show a difference of 14 Da between 
each other, and these could be used as diagnostic ions 
for the structural determination of milbemycins A3, A4, 
and D, respectively. The fragmentation of milbemycins 
A3, A4, and D shows similar patterns resulting from the 
repeated loss of water, carbon dioxide, hydrogen gas, and 
ethylene (Additional file 6: Figures S5a, S5b, and S5c).
The MS/MS spectra of milbemycins B2, B3, and 
G obtained from S. avermitilis SAMA1M7 and their 
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fragmentation pathways are presented in Additional 
file  6: Figures S5d, S5e, and S5f, respectively. The spec-
tra obtained from S. avermitilis SAMA13 were identical 
to those from S. avermitilis SAMA1M7. The identities 
of milbemycins B2, B3, and G were confirmed by their 
molecular weights and the comparison of their MS/MS 
fragmentation patterns with those of authentic milbe-
mycins A3, A4, and D. The molecular formula for milbe-
mycin B2 was determined to be C32H46O7 on the basis 
of the (−)-HRESIMS proton loss precursor peak at 
m/z = 541.3168 [M–H]− (calcd 541.3171 for C32H45O7−). 
This peak was fragmented into several product ions 
(Additional file  6: Figures S5d). The milbemycin B3 for-
mula was established as C33H48O7 on the basis of the 
(−)-HRESIMS peak at m/z 555.3312 [M–H]− (calcd 
555.3327 for C33H47O7−), which was accompanied by 
Fig. 6 Construction of S. avermitilis SAMA1M7ΔD. a Schematic diagram for construction of the aveD disruption mutant using pΔAveD. b PCR analy‑
sis for confirmation of the AveD inactivation using genomic DNA from S. avermitilis SAMA1M7ΔD. c DNA sequences of the aveD PCR product of S. 
avermitilis SAMA1M7. d DNA sequences of the inactivated aveD PCR product of S. avermitilis SAMA1M7ΔD. While TCA sequences exist in SAMA1M7 
chromosome, the stop codon TGA sequences were generated in SAMA1M7ΔD chromosome
Fig. 7 Time course analysis of milbemycin production ( ), the 
packed mycelial volume (PMV) value ( ), and the amount of total 
reducing sugar ( ) during cultivation of S. avermitilis SAMA1M7ΔD in 
a 5 l fermenter
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several product ions (Additional file 6: Figures S5e). The 
milbemycin G formula was shown to be C34H50O7 on 
the basis of the (−)-HRESIMS peak at m/z  =  569.3440 
[M–H]− (calcd 569.3484 for C34H49O7−), which also pro-
duced several product ions (Additional file 6: Figures S5f). 
Again, the common fragment ions (m/z = 321.1860 and 
109.0295) were detected, and the existence of the char-
acteristic fragmentation patterns of milbemycins B2, B3, 
and G (m/z = 143.1078, 157.1234, and 171.1391, respec-
tively) indicates that their structural difference occurred 
due to the C25 moieties. Similarly, the difference of 14 Da 
in the corresponding fragment ions within three milbe-
mycins B2, B3, and G could be used as diagnostic indica-
tors for milbemycins B2, B3, and G, respectively. Unlike 
the fragmentation patterns of milbemycins A3, A4, and D, 
loss of CH3OH as a neutral molecule from the C5-meth-
oxy group occurred in these C5-O-methylated congeners. 
These detailed results of qTOF-HR-MS/MS analysis une-
quivocally confirmed the identities of milbemycins pro-
duced from the S. avermitilis mutant strains.
Discussion
Interestingly, the nucleotide sequences of milA1 cloned 
from S. hygroscopicus subsp. aureolacrimosus are iden-
tical to those reported from S. bingchenggensis [15], and 
only 68 nucleotide sequences of milA3 (~17.5-kb) from S. 
hygroscopicus subsp. aureolacrimosus are changed com-
pared to the S. bingchenggensis sequences. Therefore, it 
seems that the horizontal transfer of PKS genes occurred 
between these two Streptomyces strains although we did 
not sequence other milbemycin biosynthetic genes or the 
genes located between milA3 and milA1. The sequences 
of milA3 of S. hygroscopicus subsp. aureolacrimosus 
have been deposited in the GenBank database under the 
accession number KY056568.
Although it has been demonstrated over the last two 
decades that the engineered PKSs can produce the 
desired compounds, low production of novel natural 
products is often encountered mainly due to the dis-
ruption of the overall enzyme integrity/interaction and 
inefficient substrate recognition/channeling along the 
engineered PKS machinery [20]. However, the well-
designed assembly of structurally and functionally 
related PKSs, such as avermectin and milbemycin PKS, 
in a previously optimized high-producing strain can 
produce large quantities of desired products as demon-
strated in this study. The host strain used in this study, 
S. avermitilis SA-01, produces approximately 1.1  mM 
of the avermectins which corresponds to approximately 
470 mg/l of the milbemycins on a molar basis in the fer-
menter culture. Although the hybrid PKS constructed in 
this study did not fully reproduce the maximum produc-
tion capacity of the host strain, the engineered strain S. 
avermitilis SAMA1M7ΔD produced approximately 247 
and 400 mg/l of milbemycins A3, A4, and D in the flask 
and fermenter culture, respectively. The productivity of 
the hybrid PKS varies mainly depending on the choice 
of promoter or host strain, fusion strategies (e.g. fusion 
sites for the domain/module substitution and the use of 
proper docking domains), and sometimes the similarity 
of mixed PKSs. The similar high titers of milbemycins 
between S. avermitilis SAMA13 and SAMA1M7 strains 
imply that the similarity between milbemycin and aver-
mectin PKSs allowed us to construct functional and 
productive hybrid PKSs either on modular or subunit 
levels with maintenance of only the docking domains, 
although It has been suggested that not only the dock-
ing domain but also other domains such as KS and AT 
domains participate in molecular recognition between 
PKSs [29].
Similarly, when a midecamycin biosynthetic gene was 
introduced into a tylosin-overproducing Streptomyces 
fradiae from which its native tylosin biosynthetic gene 
cluster was deleted, a substantial level of midecamycin 
analog (1 g/l) was obtained [30]. In another example, the 
heterologous expression of the tetracenomycin biosyn-
thetic genes in an industrial monensin producer Strep-
tomyces cinnamonensis led to the high titer production 
of tetracenomycins [31]. These previous results [22, 23, 
30, 31] together with ours shows that the overproduc-
ing feature of the industrial strains is mainly caused by 
the mutations in non-biosynthetic genes and can be uti-
lized with heterologous or engineered PKSs. Although 
the titers of milbemycins A3 and A4 in the mutant strain 
of S. bingchenggensis were reported to reach 1450  mg/l 
[18], it is notable that S. avermitilis is one of most well-
studied Streptomyces species [32] and the feasibility of 
the S. avermitilis strain in which active biosynthetic 
gene clusters were deleted for the production of a range 
of natural products has been successfully demonstrated 
[33, 34]. Therefore, although the results presented here 
were obtained using a moderately improved S. avermiti-
lis mutant, application of the same strategy to higher 
producing industrial strains and further optimization by 
metabolic engineering and synthetic biology strategies 
may allow for more improved production of the milbe-
mycins. Most importantly, the well-established genetic 
tools in S. avermitilis will facilitate further exploration of 
novel milbemycin analogs with improved properties.
It is known that AveC catalyzes the spirocyclization 
of a C17, C25-dihydroxy C21-ketone polyketide inter-
mediate containing a C23-hydroxy group to generate 
avermectin “2” series and the optional dehydration to 
yield avermectin “1” series with double bond between 
C22–C23 in S. avermitilis [17]. The hybrid PKS, where 
AveA1 was replaced with MilA1 which contains fully 
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active DH-ER-KR domains in module 2, biosynthesizes a 
polyketide intermediate without the C23-hydroxy group 
(Fig.  3). Our results along with previous studies where 
the loading module and module 2 of AveA1 or the entire 
AveA1 were replaced with the respective milbemycin 
PKS domains or subunit [22, 23] showed that AveC is 
substrate-flexible and can successfully catalyze the spiro-
cyclization of this modified intermediate producing the 
desired compounds.
Previous studies showed that the replaced milbemy-
cin loading module from S. bingchenggensis accepts only 
acetyl-CoA and propionyl-CoA to generate 25-methyl 
and 25-ethyl avermectin analogs in S. avermitilis [22, 23]. 
However, we observed the production of small amounts 
of milbemycins D and G which contain an isopropyl side 
chain at C25 (Fig. 5) implying that the loading module of 
milbemycin-avermectin hybrid PKS shows certain degree 
of substrate flexibility in the heterologous host as in the 
native producing strain. Because the sequences of MilA1 
from S. hygroscopicus subsp. aureolacrimosus are identi-
cal to those of S. bingchenggensis, this observed discrep-
ancy was probably simply due to the detection method 
used. While the produced metabolites were monitored 
only by HPLC in the previous studies [22, 23], a highly 
sensitive UPLC-qTOF-HR-MS analysis was employed in 
this study. The commercial milbemectin is a mixture of 
70% milbemycin A4 and 30% milbemycin A3. However, 
S. avermitilis SAMA1M7ΔD produced more milbemy-
cin A3 than A4 (Table 1). Therefore, further engineering 
of the AT domain in the milbemycin loading module to 
alter its substrate preference from acetyl-CoA to propio-
nyl-CoA is required to meet the ratio of milbemycin A3/
A4 in commercial milbemectin. To this end, the follow-
ing approaches can be applied: replacement of the AT 
domain with one that prefers propionyl-CoA, site-specific 
mutagenesis based on molecular docking simulation, or 
direct evolution to reprogram AT domain specificity [20].
Conclusions
These results demonstrate that large quantities of milbe-
mycins can be produced in the avermectin high-pro-
ducing S. avermitilis by expression of the engineered 
PKS which was designed to minimize adverse effects 
on protein integrity and interactions. Application of the 
same strategy in the industrial S. avermitilis will further 
increase the milbemycin titer and also allow for generat-
ing novel milbemycin analogs with improved properties 
in sufficient amounts for further development.
Methods
Bacterial strains, plasmids, culture medium, and reagents
All bacterial strains and plasmids used in this study are 
listed in Table 2. E. coli DH5α was used as a subcloning 
host for performing plasmid constructions and cultured 
at 37  °C in Luria–Bertani medium [35] supplemented 
with suitable antibiotics. S. avermitilis SA-01, an aver-
mectin high-producing strain, was employed as an initial 
strain for the construction of the milbemycin-producing 
strain. Constructs for gene replacement were generated 
with pKC1139 [27]. Non-methylating E. coli ET12567/
pUZ8002 was used as a donor strain in conjugal trans-
fer, and the conjugal transfer of recombinant plasmids 
between Streptomyces and E. coli was conducted on solid 
Mannitol-Soy flour (MS) medium [28]. Inorganic Salt 
Starch (ISP4) agar medium [36] was utilized for sporu-
lation and generation of S. avermitilis and S. hygroscopi-
cus subsp. aureolacrimosus. Isolation of genomic DNA 
from S. avermitilis and S. hygroscopicus subsp. aureolac-
rimosus were performed according to standard protocol 
using the culture grown in ISP2 liquid medium [28]. A 
genomic DNA from S. hygroscopicus subsp. aureolac-
rimosus NRRL 5739, a milbemycin-producing strain, was 
used as a template for the milA1 and milA3 genes. Since 
the nucleotide sequences of the milbemycin biosynthetic 
genes of the S. hygroscopicus subsp. aureolacrimosus 
were not known, the deoxyoligonucleotide primers for 
the cloning of milA1 and milA3 were designed based on 
the sequences of S. bingchenggensis BCW-1 (GenBank: 
CP002047.1). The DNA fragments used for the construc-
tion of replacement or inactivation plasmids were ampli-
fied by PCR with the corresponding primers (Additional 
file 2: Table S1) and template DNAs. PCR was performed 
by using GXL DNA polymerase (Takara, Shiga, Japan) 
acceding to the manufacturer’s recommended condi-
tion. All PCR products were cloned into plasmid Litmus 
28 (New England Biolabs, Ipswich, USA), pGem-T Easy 
(Promega, Madison, USA), or pCR2.1 TOPO (Invitrogen, 
Carlsbad, USA) and sequenced to confirm their authen-
ticity. DNA sequencing was performed by Cosmoge-
netech (Seoul, Korea). The authentic milbemycins A3, 
A4, and D and oligomycin A were purchased from Bio-
Australis Fine Chemicals (Sydney, Australia).
Construction of AveA1/AveA3 replacement mutant strain 
S. avermitilis SAMA13
For the replacement of the aveA1 gene with milA1 
in S. avermitilis SA-01, a plasmid pSAMA1 was con-
structed. The DNA segments encoding MilA1 (Genbank: 
CP002047.1, 10777186-10790000 nt) were obtained 
by PCR amplification. The 8.6-kb fragment (Genbank: 
CP002047.1, 10777186-10785834 nt) and the 3.8-kb frag-
ment (Genbank: CP002047.1, 10785829-10789650 nt) 
were amplified with primers A1-1F/A1-1R and A1-2F/
A1-2R, respectively. On the other hand, a 1.0-kb frag-
ment including MilA1-ACP2 (Genbank: CP002047.1, 
10789645-10790000 nt) and the C-terminal docking 
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domain of AveA1 was artificially synthesized. Addi-
tionally, a 1.3-kb upstream flanking region of aveA1 
containing the promoter region of aveA1 as well as a 
1.1-kb downstream flanking region of aveA1 contain-
ing C-terminal docking domain of AveA1 were ampli-
fied using primer pairs A1LF/A1LR and A1RF/A1RR, 
respectively. The stepwise assembly of the PCR products 
and the synthesized DNA fragment was carried out by 
conventional cloning procedures or the infusion ligation 
method, which relies on intramolecular recombination 
between the adjacent homologous DNA sequences in 
pCR2.1 TOPO according to the manufacturer’s protocol 
(Clontech Laboratories Inc, Mountain View, USA). The 
final recombinant plasmid pSAMA1 was constructed 
by transfer of the XbaI/HindIII fragment from pCR2.1 
TOPO into pKC1139. After non-methylating E. coli 
ET12567/pUZ8002 was transformed with the pSAMA1, 
conjugal transfer of the recombinant plasmid from the E. 
coli into S. avermitilis SA-01 was performed as described 
previously [28]. Exconjugants selected based on apramy-
cin resistance were verified by PCR analysis for single 
crossover homologous recombination and propagated in 
antibiotic-free ISP4 medium for second round of homol-
ogous recombination. The desired milA1 substitution 
mutant which showed no resistance to apramycin was 
confirmed by sequencing of the PCR product obtained 
using the mutant genomic DNA as a template, generating 
S. avermitilis SAMA1.
Plasmid pSAMA13 was constructed for the replace-
ment of the aveA3 gene with milA3 in S. avermitilis 
SAMA1. The DNA fragment containing milA3 (Genbank: 
CP002047.1, 10855562-10872660 nt) was prepared by 
PCR in three fragments using the listed primer pairs (A3-
1F/A3-1R, A3-2F/A3-2R, A3-3F/A3-3R; Additional file 2: 
Table S1) and ligated into pGem-T Easy, respectively, 
to provide a 3.7-kb (Genbank: CP002047.1, 10868959-
10872660 nt), a 6.7-kb (Genbank: CP002047.1, 10862242-
10868964 nt), and a 6.7-kb (Genbank: CP002047.1, 
10855562-10862247 nt) fragment. Meanwhile, the primer 
pairs, A3LF/A3LR and A3RF/A3RR were designed to 
amplify aveA3 flanking regions which contain the C- 
and N-terminal docking domain sequences of AveA3 
from the S. avermitilis SA-01, resulting in an EcoRI/MfeI 
fragment (1.2-kb) carrying the downstream region of 
aveA3 and a MfeI/HindIII fragment (1.2-kb) carrying the 
upstream region of aveA3, respectively. For seamless liga-
tion of aveA3 flanking regions to both ends of the milA3 
gene, nucleotide sequences were changed to create MfeI 
sites in which the amino acid sequences were not altered 
(CCATCG and CAGCTC → CAATTG; Additional file 1: 
Figure S1b). The fragment containing the C-terminal 
docking domain of AveA3, the fragments encoding 
Table 2 Strains and plasmids used in this study
Strain/plasmid Description Source/References
Strain
E. coli DH5α Host for plasmids construction and subcloning New England Biolabs
E. coli ET12567/pUZ8002 Non‑methylating ET12567 containing non‑transmissible RP4 derivative 
plasmid pUZ8002
Kieser et al. [28]
S. hygroscopicus subsp. aureolacrimosus NRRL 5739 The milbemycin‑producing strain Takiguchi et al. [6]
S. avermitilis SA‑01 Industrial avermectin‑producing S. avermitilis This study
S. avermitilis SAMA1 Mutant strain of S. avermitilis SA‑01 with AveA1 replaced by MilA1 This study
S. avermitilis SAMA13 Mutant strain of SAMA1 with AveA3 replaced by MilA3 This study
S. avermitilis SAMA1M7 Mutant strain of SAMA1 with AveA3‑module7 replaced by MilA3‑module7 This study
S. avermitilis SAMA1M7ΔD AveD disruption mutant of SAMA1M7 This study
Plasmid
pLitmus28 E. coli vector for subcloning, AmpR New England Biolabs
pGEM T easy E. coli vector for cloning PCR products, AmpR Promega
pCR2.1 TOPO E. coli vector for cloning PCR products, AmpR Invitrogen
pKC1139 Temperature‑sensitive E. coli‑Streptomyces shuttle vector containing oriT for 
gene substitution and disruption, AprR
Bierman et al. [27]
pSAMA1 pKC1139‑based plasmid containing aveA1 upstream fragment, entire milA1 
fragment, and aveA1 downstream fragment
This study
pSAMA13 pKC1139‑based plasmid containing aveA3 upstream fragment, entire milA3 
fragment, and aveA3 downstream fragment
This study
pSAMA1M7 pKC1139‑based plasmid containing aveA3‑module 7 upstream fragment, 
milA3‑module 7 fragment, and aveA3‑module 7 downstream fragment
This study
pΔAveD pKC1139‑based plasmid containing inactivated aveD fragment This study
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MilA3, and the fragment containing N-terminal docking 
domain of AveA3 were combined into Litmus28 through 
a series of subcloning, and the 19-kb EcoRI/HindIII frag-
ment carrying the whole combined DNA was transferred 
into the same sites of pKC1139 to generate pSAMA13. 
Following the procedure described above [28], pSAMA13 
was transformed into the strain S. avermitilis SAMA1, 
and the double crossover mutants were selected. After 
verification by PCR analysis, the obtained milA3 substi-
tution mutant was designated as S. avermitilis SAMA13.
Construction of AveA1/module7 replacement mutant 
strain S. avermitilis SAMA1M7
In order to swap the aveA3-module7 for the milA3-
module7 in S. avermitilis SAMA1, plasmid pSAMA1M7 
was constructed. PCR was performed to amplify a 3.0-kb 
XbaI/SpeI fragment containing the downstream region 
of aveA3-module7 and a 2.6-kb SpeI/HindIII fragment 
containing the upstream region and N-terminal docking 
domain sequences of aveA3 using primer pairs M7LF/
M7LR and M7RF/M7RR, respectively. A primer pair 
M7-F/M7-R was utilized for amplification of a 6.5-kb 
fragment carrying milA3-module7 region (Genbank: 
CP002047.1, 10855552-10862085 nt) from S. hygro-
scopicus subsp. aureolacrimosus genomic DNA. After 
the upstream fragment of aveA3-module7, a milA3-
module7 fragment, and downstream fragment of aveA3-
module7 were inserted to pCR2.1 TOPO, the entire 
combined fragment was transferred to pKC1139 using 
XbaI/HindIII, resulting in pSAMA1M7. The plasmid 
pSAMA1M7 was introduced into the chromosome of 
strain S. avermitilis SAMA1 following the procedures 
described [28]. The resulting double crossover mutant, 
namely S. avermitilis SAMA1M7, were verified by PCR 
amplification and sequencing of the PCR products.
Construction of AveD inactivation mutant strain S. 
avermitilis SAMA1M7ΔD
Plasmid pΔAveD carrying the truncated aveD gene was 
prepared for the inactivation of AveD. A 1.6-kb fragment 
carrying the partial upstream region of aveD was ampli-
fied by PCR using primers DD-1F/DD-1R from S. aver-
mitilis SAMA1M7 genomic DNA, in which stop codon 
TGA is generated through a nucleotide substitution 140-
bp downstream from the start codon of aveD (Additional 
file 5: Figure S4). Another 1.5-kb fragment which contains 
the partial downstream region of aveD was obtained by 
PCR amplification with primers DD-2F/DD-2R, possess-
ing 20-bp overlapping region with the 1.6-kb fragment. 
Since the fragments additionally contain homologous 
sequences with pCR2.1 TOPO, the fragments were 
ligated into pCR2.1 TOPO with the infusion ligation 
method. The XbaI/HindIII fragment was transferred into 
the same sites of pKC1139 to construct pΔAveD. The 
AveD disruption in S. avermitilis SAMA1M7 via double 
crossover homologous recombination was achieved 
according to a previously described protocol [28] to give 
S. avermitilis SAMA1M7ΔD. To genetically verify the 
disruption, PCR reaction was performed using genomic 
DNA of the mutant, and the sequencing data of the PCR 
products were compared to the sequence of the original 
aveD gene.
Production of milbemycins
Streptomyces avermitilis mutant strains were preculti-
vated in seed medium (soluble starch 30 g/l, yeast extract 
15  g/l, corn steep liquor 5  g/l, and KH2PO4 0.4  g/l, 
pH 7.2) at 28  °C for 40–48  h using a rotary shaker at 
200 rpm. After a portion of the preculture (5% v/v) was 
transferred into a 250  ml Erlenmeyer flask containing 
25 ml main medium (soluble starch 80 g/l, soybean flour 
10 g/l, skim milk 15 g/l, and KH2PO4 0.5 g/l, KCl 10 g/l, 
pH 7.0), cultivation was carried out for the production of 
milbemycins at 28 °C for 14 days at 230 rpm. The result-
ing culture broth was mixed with an equal volume of 
acetonitrile:methanol = 1:1 solution or ethyl acetate, and 
sonication was also conducted in an ultrasonic cleaner 
for 10  min. The resultant mixture was centrifuged for 
5  min and the supernatant was analyzed. For the pro-
duction of milbemycins in a fermenter, a seed medium 
composed of glucose monohydrate 20 g/l, soybean flour 
15  g/l, yeast extract 5  g/l, and corn steep powder 3  g/l 
with pH 7.0 was used. Respective strains were cultivated 
in two 1  l Erlenmeyer flasks containing 100  ml seed 
medium at 28 °C using a shaking incubator at 200 rpm. 
After cultivation for 24  h, 150  ml of seed cultures was 
transferred into 5 l fermenter (Biotron GX, Hanil science 
medical, Daejeon, Korea) containing 3  l main medium. 
The culture was grown at 28  °C and dissolved oxygen 
level was maintained over 30% through aeration in 0.5–1 
vvm and varying stirring speed. The pH was maintained 
at 6.8 during idiophase. Cell growth was estimated by 
measuring the packed mycelial volume (PMV) from 
10 ml fermented broth centrifuged in a 15 ml conic scale 
tube at 3000 rpm for 10 min. After acid hydrolysis of the 
supernatant of the fermented broth, total reducing sugar 
was measured by dinitrosalicylic acid method [37]. The 
resulting culture broth was extracted as described above 
and analyzed.
HPLC and UPLC‑qTOF‑HR‑MS/MS analysis of milbemycins
The organic extracts were applied to HPLC coupled with 
a photodiode array (PDA) detector and UPLC combined 
with a quadrupole-time of flight high resolution mass 
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spectrometry (qTOF-HR-MS). HPLC was performed 
with analytical Phenomenex Luna (4.6 × 100 mm, 5 μm) 
column on an YL9100 HPLC system (YL Instrument 
Co, Anyang, Korea) consisting of a YL9110 gradient 
pump coupled with a YL9160 PDA detector with 1024 
channels. A gradient elution using solvent A (0.05% trif-
luoroacetic acid in water) and solvent B (acetonitrile) as 
the mobile phase at a flow rate of 1 ml/min was applied. 
The gradient conditions were as follows: 0–5 min, linear 
at 40% B; 5–35 min, linear from 40 to 90% B; 35–55 min 
held at 90% B, then returned to 40% B in 5  min. The 
injection volume was 20  μl. The absorption spectra of 
eluted compounds were scanned within 190–600  nm 
using the in-line PDA detector monitored at 245 nm for 
milbemycin A3, A4, D, B2, B3, and G. Authentic milbe-
mycins A3, A4, and D (BioAustralis Fine Chemicals), 
were used to generate calibration curves. The reported 
production levels of milbemycins are the average based 
on five separate cultivations and extractions.
The six milbemycins were further identified with a 
Waters XEVO® G2S Q-TOF mass spectrometer coupled 
with a Waters Acquity UPLC® system equipped with a 
Xselect® CSH column XP (2.1 × 100 mm, 2.5 μm) con-
sisting of an Acquity I-Class system. A gradient elution 
using solvent A (water) and solvent B (acetonitrile) as the 
mobile phase at a flow rate of 0.4  ml/min was applied. 
The gradient conditions were as follows: 0–1 min, linear 
at 50% B; 1–7 min, linear from 50 to 75% B; 7–15 min, 
linear from 75 to 90% B; 15–18 min held at 90% B, then 
returned to 50% B in 2  min. The injection volume was 
4  μl. The MS system was operated in electrospray ioni-
zation (ESI) with a negative ionization mode. The typical 
operating parameters were as follows: analyser, resolu-
tion mode; capillary voltage (volt.), 2.5 kV; sampling cone 
volt., 25  V; source temperature (temp.), 120  °C, source 
offset temp., 80  °C; desolvation temp., 300  °C; cone gas 
flow, 10  l/h; desolvation gas flow, 600  l/h. The analyzer 
was operated with an extended dynamic range at 10 000 
resolution (fwhm at m/z 554) with an acquisition time of 
0.1 s. Leucine encephalin was used as a lockspray and a 
reference material for mass spectrometer tuning and cali-
bration. Leucine enkephalin (400 pg/µl, acetonitrile:water 
(0.1% formic acid), 50:50 by volume con) was infused 
at a rate of 5  µl/min for mass correction. Mass spectra 
were acquired with a scan range of 50–700 amu with 
scan time 0.1 s. For MS/MS analysis, helium collision gas 
was introduced in accordance with the manufacturer’s 
recommendations. The MS/MS fragment spectra were 
produced using collision energy 20  eV for set mass val-
ues m/z =  527.3014, 541.3171, 555.3327, and 569.3484. 
MassLynx V4.1 software (Waters) was used for instru-
ment control, acquisition, and sample analysis (Waters 
Co, Milford, USA).
Abbreviations
ACP: acyl carrier protein; AT: acyltransferase; DH: dehydratase; ER: enoylreduc‑
tase; KR: ketoreductase; KS: ketosynthase; PKS: polyketide synthase; PMV: 
packed mycelial volume; ESI: electrospray ionization; HPLC: high‑performance 
liquid chromatography; HRESIMS: high‑resolution electrospray ionization 
mass spectrometry; PDA: photodiode array; qTOF‑HR‑MS: quadrupole‑time 
of flight high resolution mass spectrometry; UPLC: ultra‑performance liquid 
chromatography.
Authors’ contributions
KHO and YJY designed research and wrote the paper. MSK, NRL, WJC, SWP, KK, 
and EK conducted biological experiments. MCS and SJN performed analytical 
experiments. All authors read and approved the final manuscript.
Author details
1 Department of Chemistry and Nano Science, Ewha Womans University, 
52, Ewhayeodae‑gil, Seoul 03760, Republic of Korea. 2 Crop Protection R&D 
Center, FarmHannong Co., Ltd, 39‑23, Dongan‑ro 1113beon‑gil, Yeonmu‑eup, 
Nonsan‑si, Chungcheongnam‑do 33010, Republic of Korea. 3 Present 
Address: Department of Bioinformatics, Bio Campus of Korea Polytechnic, 
48, Dongan‑ro 112‑gil, Ganggyeong‑eup, Nonsan‑si, Chungcheongnam‑do 
32943, Republic of Korea. 
Acknowledgements
We thank Dr. Kris Rathwell for critically reading this manuscript.
Competing interests
Provisional patent applications covering this work have been filed.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article and its additional files.
Funding
This work was supported by Advanced Production Technology Development 
Program, Ministry of Agriculture, Food and Rural Affairs (114048‑03‑3‑CG000), 
Republic of Korea, the Basic Science Research Program through the National 
Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and 
Future Planning (MISP) (2016R1A2A1A05005078) and by Ministry of Education 
(2016R1A6A3A11930649), and the Intelligent Synthetic Biology Center of the 
Global Frontier Project funded by MISP (20110031961), Republic of Korea.
Received: 15 November 2016   Accepted: 4 January 2017
References
 1. Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R, Kong YL, 
Monaghan RL, Olson G, Putter I, Tunac JB, Warrick H, Stapley EO, Oiwa 
R, Omura S. Avermectins, new family of potent anthelmintic agents: 
producing organism and fermentation. Antimicrob Agents Chemother. 
1979;15(3):361–7.
Additional files
Additional file 1: Figure S1. The engineered fusion sites for hybrid PKSs.
Additional file 2: Table S1. Primers used for construction of plasmids 
and verification of mutant strains.
Additional file 3: Figure S2. HPLC analysis of milbemycins produced 
from S. avermitilis mutant strains and authentic standard milbemycins.
Additional file 4: Figure S3 MS/MS spectrum of oligomycin A produced 
from S. avermitilis mutant strains.
Additional file 5: Figure S4. Sequence of inactivated aveD.
Additional file 6: Figure S5. MS/MS spectra of milbemycins produced 
from S. avermitilis mutant strains.
Page 16 of 16Kim et al. Microb Cell Fact  (2017) 16:9 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 2. Egerton JR, Ostlind DA, Blair LS, Eary CH, Suhayda D, Cifelli S, Riek 
RF, Campbell WC. Avermectins, new family of potent anthelmintic 
agents: efficacy of the B1a component. Antimicrob Agents Chemother. 
1979;15(3):372–8.
 3. Ikeda H, Omura S. Avermectin biosynthesis. Chem Rev. 
1997;97(7):2591–610.
 4. Shoop W, Soll M. Ivermectin, abamectin and eprinomectin. In: Vercruysse 
J, Rew RS, editors. Macrocyclic lactones in antiparasitic therapy. Walling‑
ford: CABI Publishing; 2002. p. 1–11.
 5. Thuan NH, Pandey RP, Sohng JK. Recent advances in biochemistry and 
biotechnological synthesis of avermectins and their derivatives. Appl 
Microbiol Biotechnol. 2014;98(18):7747–59.
 6. Takiguchi Y, Mishima H, Okuda M, Terao M, Aoki A, Fukuda R. Milbemy‑
cins, a new family of macrolide antibiotics: fermentation, isolation and 
physico‑chemical properties. J Antibiot. 1980;33(10):1120–7.
 7. Xiang WS, Wang JD, Wang XJ, Zhang J. Two new β‑class milbemycins 
from Streptomyces bingchenggensis: fermentation, isolation, structure 
elucidation and biological properties. J Antibiot. 2007;60(6):351–6.
 8. Xiang WS, Wang JD, Fan HM, Wang XJ, Zhang J. New seco‑milbemycins 
from Streptomyces bingchenggensis: fermentation, isolation and structure 
elucidation. J Antibiot. 2008;61(1):27–32.
 9. Shoop WL, Mrozik H, Fisher MH. Structure and activity of avermectins and 
milbemycins in animal health. Vet Parasitol. 1995;59(2):139–56.
 10. Lumaret JP, Errouissi F, Floate K, Rombke J, Wardhaugh K. A review on the 
toxicity and non‑target effects of macrocyclic lactones in terrestrial and 
aquatic environments. Curr Pharm Biotechnol. 2012;13(6):1004–60.
 11. Putter I. Milbemycin compounds as anthelmintic agents. Patent US 
4144352 A; 1979.
 12. Takeshiba H, Sato K, Yanai T, Yokoi S, Ichinose R. Insecticidal milbemycin 
derivative having oxime group‑containing substituent group at 13‑posi‑
tion. Patent JP 09143183; 1997.
 13. Jung M, Saito A, Buescher G, Maurer M, Graf JF. Milbemycin oxime. In: Ver‑
cruysse J, Rew RS, editors. Macrocyclic lactones in antiparasitic therapy. 
Wallingford: CABI Publishing; 2002. p. 51–74.
 14. He Y, Sun Y, Liu T, Zhou X, Bai L, Deng Z. Cloning of separate meilingmycin 
biosynthesis gene clusters by use of acyltransferase‑ketoreductase dido‑
main PCR amplification. Appl Environ Microbiol. 2010;76(10):3283–92.
 15. Wang XJ, Yan YJ, Zhang B, An J, Wang JJ, Tian J, Jiang L, Chen YH, Huang 
SX, Yin M, Zhang J, Gao AL, Liu CX, Zhu ZX, Xiang WS. Genome sequence 
of the milbemycin‑producing bacterium Streptomyces bingchenggensis. J 
Bacteriol. 2010;192(17):4526–7.
 16. Ikeda H, Nonomiya T, Usami M, Ohta T, Omura S. Organization of 
the biosynthetic gene cluster for the polyketide anthelmintic mac‑
rolide avermectin in Streptomyces avermitilis. Proc Natl Acad Sci USA. 
1999;96(17):9509–14.
 17. Sun P, Zhao Q, Yu F, Zhang H, Wu Z, Wang Y, Wang Y, Zhang Q, Liu W. 
Spiroketal formation and modification in avermectin biosynthesis 
involves a dual activity of AveC. J Am Chem Soc. 2013;135(4):1540–8.
 18. Wang XJ, Wang XC, Xiang WS. Improvement of milbemycin‑producing 
Streptomyces bingchenggensis by rational screening of ultraviolet‑
and chemically induced mutants. World J Microbiol Biotechnol. 
2009;25(6):1051–6.
 19. Zhang J, An J, Wang JJ, Yan YJ, He HR, Wang XJ, Xiang WS. Genetic engi‑
neering of Streptomyces bingchenggensis to produce milbemycins A3/A4 
as main components and eliminate the biosynthesis of nanchangmycin. 
Appl Microbiol Biotechnol. 2013;97(23):10091–101.
 20. Kim E, Moore BS, Yoon YJ. Reinvigorating natural product combinatorial 
biosynthesis with synthetic biology. Nat Chem Biol. 2015;11(9):649–59.
 21. Rodriguez E, Hu Z, Ou S, Volchegursky Y, Hutchinson CR, McDaniel 
R. Rapid engineering of polyketide overproduction by gene trans‑
fer to industrially optimized strains. J Ind Microbiol Biotechnol. 
2003;30(8):480–8.
 22. Huang J, Chen AL, Zhang H, Yu Z, Li MH, Li N, Lin JT, Bai H, Wang JD, 
Zheng YG. Gene replacement for the generation of designed novel aver‑
mectin derivatives with enhanced acaricidal and nematicidal activities. 
Appl Environ Microbiol. 2015;81(16):5326–34.
 23. Zhang J, Yan YJ, An J, Huang SX, Wang XJ, Xiang WS. Designed biosyn‑
thesis of 25‑methyl and 25‑ethyl ivermectin with enhanced insecticidal 
activity by domain swap of avermectin polyketide synthase. Microb Cell 
Fact. 2015;14:152.
 24. Ikeda H, Wang LR, Ohta T, Inokoshi J, Omura S. Cloning of the gene 
encoding avermectin B 5‑O‑methyltransferase in avermectin‑producing 
Streptomyces avermitilis. Gene. 1998;206(2):175–80.
 25. Gokhale RS, Tsuji SY, Cane DE, Khosla C. Dissecting and exploit‑
ing intermodular communication in polyketide synthases. Science. 
1999;284(5413):482–5.
 26. Broadhurst RW, Nietlispach D, Wheatcroft MP, Leadlay PF, Weissman KJ. 
The structure of docking domains in modular polyketide synthases. 
Chem Biol. 2003;10(8):723–31.
 27. Bierman M, Logan R, O’Brien K, Seno ET, Rao RN, Schoner BE. Plasmid 
cloning vectors for the conjugal transfer of DNA from Escherichia coli to 
Streptomyces spp. Gene. 1992;116(1):43–9.
 28. Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA. Practical Strepto-
myces genetics. Norwich: The John Innes Foundation; 2000.
 29. Kapur S, Chen AY, Cane DE, Khosla C. Molecular recognition between 
ketosynthase and acyl carrier protein domains of the 6‑deoxyeryth‑
ronolide B synthase. Proc Natl Acad Sci USA. 2010;107(51):22066–71.
 30. Rodriguez E, Ward S, Fu H, Revill WP, McDaniel R, Katz L. Engineered 
biosynthesis of 16‑membered macrolides that require methoxymalonyl‑
ACP precursors in Streptomyces fradiae. Appl Microbiol Biotechnol. 
2004;66(1):85–91.
 31. Li C, Hazzard C, Florova G, Reynolds KA. High titer production of tetra‑
cenomycins by heterologous expression of the pathway in a Strepto-
myces cinnamonensis industrial monensin producer strain. Metab Eng. 
2009;11(6):319–27.
 32. Ikeda H, Ishikawa J, Hanamoto A, Shinose M, Kikuchi H, Shiba T, Sakaki 
Y, Hattori M, Omura S. Complete genome sequence and comparative 
analysis of the industrial microorganism Streptomyces avermitilis. Nat 
Biotechnol. 2003;21(5):526–31.
 33. Komatsu M, Uchiyama T, Omura S, Cane DE, Ikeda H. Genome‑minimized 
Streptomyces host for the heterologous expression of secondary metabo‑
lism. Proc Natl Acad Sci USA. 2010;107(6):2646–51.
 34. Komatsu M, Komatsu K, Koiwai H, Yamada Y, Kozone I, Izumikawa M, 
Hashimoto J, Takagi M, Omura S, Shin‑ya K, Cane DE, Ikeda H. Engineered 
Streptomyces avermitilis host for heterologous expression of biosynthetic 
gene cluster for secondary metabolites. ACS Synth Biol. 2013;2(7):384–96.
 35. Green MR, Sambrook J. Molecular cloning: a laboratory manual. 4th ed. 
New York: Cold Spring Harbor Laboratory Press; 2001.
 36. Takahashi Y, Matsumoto A, Seino A, Ueno J, Iwai Y, Omura S. Streptomyces 
avermectinius sp. nov., an avermectin‑producing strain. Int J Syst Evol 
Microbiol. 2002;52(Pt 6):2163–8.
 37. Miller GL. Use of dinitrosalicylic acid reagent for determination of reduc‑
ing sugar. Anal Chem. 1959;31(3):426–8.
